Endologix Inc (ELGX) 12.68 $ELGX
Endologix Reports Positive Clinical Data on the Nellix EVAS System from a Multicenter Study in Italy
GlobeNewswire - Thu Jun 09, 8:33AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today positive clinical data from the Italian Research Nellix Endoprosthesis ("IRENE"
study at the 2016 Society of Vascular Surgery ("SVS" Annual Meeting. This retrospective, multicenter study was designed to evaluate the Nellix(R) EndoVascular Aneurysm Sealing System ("Nellix EVAS System" for the endovascular repair of infrarenal abdominal aortic aneurysms ("AAA".
ELGX: 12.68 (-0.03)
Medical Instruments & Supplies Equities Roundup -- Endologix, Becton Dickinson, Waters, and OraSure Technologies
PR Newswire - Thu Jun 09, 7:25AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Endologix Inc. (NASDAQ: ELGX), Becton, Dickinson and Company (NYSE: BDX), Waters Corporation (NYSE: WAT), and OraSure Technologies Inc. (NASDAQ: OSUR). Learn more about these stocks by accessing their free trade alerts at:
BDX: 169.29 (-0.94), ELGX: 12.68 (-0.03), WAT: 138.04 (-2.01), OSUR: 7.78 (-0.13)
Endologix Up 45.6% Since SmarTrend Uptrend Call (ELGX)
Comtex SmarTrend(R) - Fri Jun 03, 12:48PM CDT
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on March 2nd, 2016 at $8.78. In approximately 3 months, Endologix has returned 45.56% as of today's recent price of $12.78.
ELGX: 12.68 (-0.03)
Endologix to Present at Jefferies Healthcare Conference
GlobeNewswire - Fri Jun 03, 8:00AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today it will present at the Jefferies Healthcare Conference in New York, NY.
ELGX: 12.68 (-0.03)
Endologix Has Returned 45.0% Since SmarTrend Recommendation (ELGX)
Comtex SmarTrend(R) - Fri May 27, 12:32AM CDT
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on March 2nd, 2016 at $8.78. In approximately 3 months, Endologix has returned 44.99% as of today's recent price of $12.73.
ELGX: 12.68 (-0.03)
After Yesterday's Rally of 3.49% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu May 26, 3:21PM CDT
Endologix (NASDAQ:ELGX) traded in a range yesterday that spanned from a low of $12.33 to a high of $12.93. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $12.59 on volume of 979,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ELGX: 12.68 (-0.03)
Endologix Reports Positive Clinical Data from the Nellix EVAS FORWARD-IDE Study
GlobeNewswire - Thu May 26, 8:00AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today positive clinical data from the Nellix investigational device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study (www.clinicaltrials.gov, NCT01726257). This multicenter, prospective, single arm clinical study is designed to evaluate the safety and effectiveness of the Nellix(R) EndoVascular Aneurysm Sealing System ("Nellix EVAS System" for the endovascular repair of infrarenal abdominal aortic aneurysms ("AAA". The data from the EVAS FORWARD-IDE study demonstrated that the Nellix EVAS System met the study primary endpoints for major adverse events at 30 days (safety) and Treatment Success at one year (effectiveness).
ELGX: 12.68 (-0.03)
36.2% Return Seen to Date on SmarTrend Endologix Call (ELGX)
Comtex SmarTrend(R) - Thu May 19, 1:01PM CDT
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on March 2nd, 2016 at $8.78. In approximately 3 months, Endologix has returned 36.22% as of today's recent price of $11.96.
ELGX: 12.68 (-0.03)
Endologix Completes Patient Enrollment in the Ovation(R) LIFE (Least Invasive Fast-Track EVAR) Study
GlobeNewswire - Mon May 16, 8:00AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has completed patient enrollment in the LIFE study, a multi-center post-market registry designed to evaluate the Ovation Abdominal Stent Graft Platform when used in the treatment of patients with abdominal aortic aneurysms ("AAA" using a Fast-Track EVAR protocol. The LIFE study is the first of its kind using a Fast-Track EVAR protocol, which includes bi-lateral percutaneous access enabled by the Ovation Platform ultra-low profile (14F) design, avoidance of general anesthesia and intensive care unit ("ICU" admission post procedure, and next-day discharge.
ELGX: 12.68 (-0.03)
Endologix Reports Results for the First Quarter 2016
GlobeNewswire - Mon May 09, 3:07PM CDT
Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2016.
ELGX: 12.68 (-0.03)
Shares of ELGX Up 24.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed May 04, 1:25PM CDT
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on March 2nd, 2016 at $8.78. In approximately 2 months, Endologix has returned 24.26% as of today's recent price of $10.91.
ELGX: 12.68 (-0.03)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Endologix, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Wed May 04, 10:19AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Endologix, Inc. (NASDAQ:ELGX).
ELGX: 12.68 (-0.03)
Endologix to Participate in Two Investor Conferences in May
GlobeNewswire - Fri Apr 29, 8:00AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to participate at two investor conferences in May. The first conference is the Deutsche Bank 41 Annual Health Care Conference in Boston, Massachusetts.
DB: 15.74 (-0.97), ELGX: 12.68 (-0.03)
Positive Nellix Clinical Data from the ASCEND Study for the Treatment of Juxta and Pararenal AAA Presented at the 38th Annual Charing Cross Symposium
GlobeNewswire - Thu Apr 28, 11:15AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the first data presentation from the ASCEND Registry (Aneurysm Study for Complex AAA: Evaluation of Nellix Durability), a physician-initiated registry of the Nellix EndoVascular Aneurysm Sealing System ("Nellix EVAS System" used with aortic branch stent grafts for the treatment of patients with complex abdominal aortic aneurysms ("AAAs". Professor Matthew Thompson, MD, Professor of Vascular Surgery, St. Georges Vascular Institute, London, and one of the principal investigators of the ASCEND Registry, presented the results at the 38th Annual Charing Cross Symposium being held April 26-29 in London, UK. The Nellix EVAS System is approved for investigational use only in the U.S.
ELGX: 12.68 (-0.03)
Endologix to Report First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Tue Apr 19, 3:00PM CDT
Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its first quarter 2016 financial results, which will take place on Monday, May 9, 2016 after the close of the market.
ELGX: 12.68 (-0.03)
Endologix Shares Up 22.8% Since SmarTrend's Buy Recommendation (ELGX)
Comtex SmarTrend(R) - Tue Apr 19, 1:54PM CDT
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on March 2nd, 2016 at $8.78. In approximately 2 months, Endologix has returned 22.78% as of today's recent price of $10.78.
ELGX: 12.68 (-0.03)
Endologix Announces CE Mark for Next-Generation Nellix(R) EndoVascular Aneurysm Sealing System
GlobeNewswire - Mon Apr 11, 1:25PM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today achievement of CE (Conformite Europeenne) Mark of the next-generation Nellix Endovascular Aneurysm Sealing System ("Nellix EVAS System". The first procedures with the new Nellix EVAS System were performed by Associate Professor Andrew Holden and Dr. Andrew Hill at Auckland City Hospital, Auckland, New Zealand.
ELGX: 12.68 (-0.03)
Endologix Announces First Patients in Japan Treated With Nellix(R) EndoVascular Aneurysm Sealing System
GlobeNewswire - Tue Mar 08, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first two patients with abdominal aortic aneurysms ("AAAs" in Japan have been treated with the Nellix EndoVascular Aneurysm Sealing System ("Nellix EVAS System". The patients were treated under Japan's "compassionate use" system, which grants access to physicians for use of medical treatments not yet approved in Japan for patients who are diagnosed with advanced diseases that are not responsive to existing treatment options. The procedures were performed by Toru Kuratani, MD, Ph.D., Chairman of the Department of Minimally Invasive Cardiovascular Medicine at Osaka University Graduate School of Medicine.
ELGX: 12.68 (-0.03)
Endologix Reports Positive Clinical Data on the Nellix EVAS System from a Multicenter Study in Italy
GlobeNewswire - Thu Jun 09, 8:33AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today positive clinical data from the Italian Research Nellix Endoprosthesis ("IRENE"
study at the 2016 Society of Vascular Surgery ("SVS" Annual Meeting. This retrospective, multicenter study was designed to evaluate the Nellix(R) EndoVascular Aneurysm Sealing System ("Nellix EVAS System" for the endovascular repair of infrarenal abdominal aortic aneurysms ("AAA". ELGX: 12.68 (-0.03)
Medical Instruments & Supplies Equities Roundup -- Endologix, Becton Dickinson, Waters, and OraSure Technologies
PR Newswire - Thu Jun 09, 7:25AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Endologix Inc. (NASDAQ: ELGX), Becton, Dickinson and Company (NYSE: BDX), Waters Corporation (NYSE: WAT), and OraSure Technologies Inc. (NASDAQ: OSUR). Learn more about these stocks by accessing their free trade alerts at:
BDX: 169.29 (-0.94), ELGX: 12.68 (-0.03), WAT: 138.04 (-2.01), OSUR: 7.78 (-0.13)
Endologix Up 45.6% Since SmarTrend Uptrend Call (ELGX)
Comtex SmarTrend(R) - Fri Jun 03, 12:48PM CDT
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on March 2nd, 2016 at $8.78. In approximately 3 months, Endologix has returned 45.56% as of today's recent price of $12.78.
ELGX: 12.68 (-0.03)
Endologix to Present at Jefferies Healthcare Conference
GlobeNewswire - Fri Jun 03, 8:00AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today it will present at the Jefferies Healthcare Conference in New York, NY.
ELGX: 12.68 (-0.03)
Endologix Has Returned 45.0% Since SmarTrend Recommendation (ELGX)
Comtex SmarTrend(R) - Fri May 27, 12:32AM CDT
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on March 2nd, 2016 at $8.78. In approximately 3 months, Endologix has returned 44.99% as of today's recent price of $12.73.
ELGX: 12.68 (-0.03)
After Yesterday's Rally of 3.49% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu May 26, 3:21PM CDT
Endologix (NASDAQ:ELGX) traded in a range yesterday that spanned from a low of $12.33 to a high of $12.93. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $12.59 on volume of 979,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ELGX: 12.68 (-0.03)
Endologix Reports Positive Clinical Data from the Nellix EVAS FORWARD-IDE Study
GlobeNewswire - Thu May 26, 8:00AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today positive clinical data from the Nellix investigational device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study (www.clinicaltrials.gov, NCT01726257). This multicenter, prospective, single arm clinical study is designed to evaluate the safety and effectiveness of the Nellix(R) EndoVascular Aneurysm Sealing System ("Nellix EVAS System"
for the endovascular repair of infrarenal abdominal aortic aneurysms ("AAA". The data from the EVAS FORWARD-IDE study demonstrated that the Nellix EVAS System met the study primary endpoints for major adverse events at 30 days (safety) and Treatment Success at one year (effectiveness). ELGX: 12.68 (-0.03)
36.2% Return Seen to Date on SmarTrend Endologix Call (ELGX)
Comtex SmarTrend(R) - Thu May 19, 1:01PM CDT
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on March 2nd, 2016 at $8.78. In approximately 3 months, Endologix has returned 36.22% as of today's recent price of $11.96.
ELGX: 12.68 (-0.03)
Endologix Completes Patient Enrollment in the Ovation(R) LIFE (Least Invasive Fast-Track EVAR) Study
GlobeNewswire - Mon May 16, 8:00AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has completed patient enrollment in the LIFE study, a multi-center post-market registry designed to evaluate the Ovation Abdominal Stent Graft Platform when used in the treatment of patients with abdominal aortic aneurysms ("AAA"
using a Fast-Track EVAR protocol. The LIFE study is the first of its kind using a Fast-Track EVAR protocol, which includes bi-lateral percutaneous access enabled by the Ovation Platform ultra-low profile (14F) design, avoidance of general anesthesia and intensive care unit ("ICU" admission post procedure, and next-day discharge. ELGX: 12.68 (-0.03)
Endologix Reports Results for the First Quarter 2016
GlobeNewswire - Mon May 09, 3:07PM CDT
Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2016.
ELGX: 12.68 (-0.03)
Shares of ELGX Up 24.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed May 04, 1:25PM CDT
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on March 2nd, 2016 at $8.78. In approximately 2 months, Endologix has returned 24.26% as of today's recent price of $10.91.
ELGX: 12.68 (-0.03)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Endologix, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Wed May 04, 10:19AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Endologix, Inc. (NASDAQ:ELGX).
ELGX: 12.68 (-0.03)
Endologix to Participate in Two Investor Conferences in May
GlobeNewswire - Fri Apr 29, 8:00AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to participate at two investor conferences in May. The first conference is the Deutsche Bank 41 Annual Health Care Conference in Boston, Massachusetts.
DB: 15.74 (-0.97), ELGX: 12.68 (-0.03)
Positive Nellix Clinical Data from the ASCEND Study for the Treatment of Juxta and Pararenal AAA Presented at the 38th Annual Charing Cross Symposium
GlobeNewswire - Thu Apr 28, 11:15AM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the first data presentation from the ASCEND Registry (Aneurysm Study for Complex AAA: Evaluation of Nellix Durability), a physician-initiated registry of the Nellix EndoVascular Aneurysm Sealing System ("Nellix EVAS System"
used with aortic branch stent grafts for the treatment of patients with complex abdominal aortic aneurysms ("AAAs". Professor Matthew Thompson, MD, Professor of Vascular Surgery, St. Georges Vascular Institute, London, and one of the principal investigators of the ASCEND Registry, presented the results at the 38th Annual Charing Cross Symposium being held April 26-29 in London, UK. The Nellix EVAS System is approved for investigational use only in the U.S. ELGX: 12.68 (-0.03)
Endologix to Report First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Tue Apr 19, 3:00PM CDT
Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its first quarter 2016 financial results, which will take place on Monday, May 9, 2016 after the close of the market.
ELGX: 12.68 (-0.03)
Endologix Shares Up 22.8% Since SmarTrend's Buy Recommendation (ELGX)
Comtex SmarTrend(R) - Tue Apr 19, 1:54PM CDT
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on March 2nd, 2016 at $8.78. In approximately 2 months, Endologix has returned 22.78% as of today's recent price of $10.78.
ELGX: 12.68 (-0.03)
Endologix Announces CE Mark for Next-Generation Nellix(R) EndoVascular Aneurysm Sealing System
GlobeNewswire - Mon Apr 11, 1:25PM CDT
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today achievement of CE (Conformite Europeenne) Mark of the next-generation Nellix Endovascular Aneurysm Sealing System ("Nellix EVAS System"
. The first procedures with the new Nellix EVAS System were performed by Associate Professor Andrew Holden and Dr. Andrew Hill at Auckland City Hospital, Auckland, New Zealand. ELGX: 12.68 (-0.03)
Endologix Announces First Patients in Japan Treated With Nellix(R) EndoVascular Aneurysm Sealing System
GlobeNewswire - Tue Mar 08, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first two patients with abdominal aortic aneurysms ("AAAs"
in Japan have been treated with the Nellix EndoVascular Aneurysm Sealing System ("Nellix EVAS System". The patients were treated under Japan's "compassionate use" system, which grants access to physicians for use of medical treatments not yet approved in Japan for patients who are diagnosed with advanced diseases that are not responsive to existing treatment options. The procedures were performed by Toru Kuratani, MD, Ph.D., Chairman of the Department of Minimally Invasive Cardiovascular Medicine at Osaka University Graduate School of Medicine. ELGX: 12.68 (-0.03)
